Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 88

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 88
---
2015, we entered
into an exclusive license agreement with Immune Ventures, LLC (Immune Ventures). The license agreement relates to our natural killer program,
INKmune. Immune Ventures is owned by our RJ Tesi, our CEO and Chairman of the Board of Directors, David Moss, our Chief Financial Officer
and Treasurer and Mark Lowdell, our Chief Scientific Officer. Because our officers and directors also own Immune Ventures there may be
an inherent conflict of interest which could result in unanticipated actions that adversely affect us.

Changes in U.S. patent law could diminish
the value of patents in general, thereby impairing our ability to protect our products.

As is the case with other
biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing
patents in the biopharmaceutical industry involves both technological and legal complexity and is costly, time-consuming and inherently
uncertain. For example, on September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith
Act included a number of significant changes to U.S. patent law, including provisions that affect the way patent applications will be
prosecuted and that may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March
2013 to a “first to file” system in which the first inventor to file a patent application is typically entitled to the patent.
Third parties are allowed to submit prior art before the issuance of a patent by the USPTO, and may become involved in post-grant proceedings,
including opposition, derivation, reexamination, inter partes review or interference proceedings challenging our patent rights or the
patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope or enforceability
of, or invalidate, our patent rights, which could adversely affect our competitive position.

In addition, the U.S. Supreme
Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances
or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain
patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending
on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents